Citation:Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al 2014

Citation

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014 Sep;15(10):1065-75 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25088940.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Introduction: the role of systemic therapies in non-resectable metastatic disease
2. Molecular pathology and biomarkers – implications for systemic therapy